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Abstract

Background—Uterine leiomyomas, or fibroids, are prevalent tumors that are dependent
on sex steroids for growth. Clinically, progesterone promotes fibroid growth and anti-progestins
cause a durable reduction in fibroid size, yet the mechanisms underlying progesterone action are
unclear. A-kinase anchoring protein 13 (AKAP-13, also known as AKAP-Brx) functions as a
Rho-GEF and is over-expressed in fibroids. AKAP-Brx has been shown to activate estrogen and
glucocorticoid receptors, and bind these receptors via a nuclear receptor-binding motif. However,
it is not known whether AKAP-Brx also binds progesterone receptor or augments progesterone
action. Objective—The purpose of this study was to determine if AKAP-Brx affected the activity
of progesterone receptor B (PR-B), the more active isoform of the nuclear progesterone receptors.
Design—Controlled laboratory research studies. Results—AKAP-Brx more than doubled
progesterone-dependent gene activation by PR-B in two cell lines, including Cos7 cells and
immortalized fibroid cells, and for two hormone dependent promoters. On the contrary, silencing
of AKAP-Brx via RNA interference reduced progesterone dependent gene activation of
endogenous PR-B-controlled-genes in a dose-dependent manner. In vitro and ex vivo binding
studies suggest that AKAP-Brx and PR-B interact directly. Inhibition of MEK reduced AKAPBrx enhancement of PR-B activity, suggesting that AKAP-Brx may affect PR-B via a pathway
involving p44/42 MAPK (ERK1/2) phosphorylation. Inhibition of p38 MAPK, on the other hand,
did not affect PR-B activation by AKAP-Brx. Conclusion—This is the first report that AKAP-Brx
augments gene activation by PR-B in a ligand-dependent manner in various cell types, including
fibroids. AKAP-Brx may bind directly to PR-B and enhance its activity via ERK1/2
phosphorylation. These data suggest that the increased expression of AKAP-Brx in fibroids could
promote progesterone-mediated fibroid growth.
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Introduction

Uterine leiomyomas, or fibroids, are prevalent benign growths in the uterus that
represent a significant health problem for millions of women. Grossly, uterine fibroids
are large, stiff, rubbery masses that are dependent on sex steroids for growth. While the
cause of uterine fibroids remains unclear, clinically, high-progesterone states such as
pregnancy promote fibroid growth.1-4 Treatment of women with progesterone results in
increased cellularity and mitotic activity in the leiomyomas,5 whereas the synthetic antiprogestin mifepristone6-9 and selective-progesterone-receptor-modulators (SPRMs) like
Asoprisnil (J687)10,11 and Ulipristal (CDB-2914)12-15 cause a durable reduction in fibroid
size in a significant proportion of treated women. In vitro effects of anti-progestins
include reduced proliferation, induction of apoptosis, reduction of extracellular matrix
deposition, and reduction of growth factor expression, suggesting a clear link between
progesterone and fibroid growth.12,16
The effects of progesterone in the uterus and other reproductive tissues are due to
changes in gene expression modulated by the progesterone receptors (PRs). PRs are
members of the nuclear hormone receptor superfamily of transcription factors. After
being activated by binding progesterone, PRs activate transcription of hormoneresponsive genes. Nuclear PRs exist in two isoforms, designated PR-A and PR-B. PR-B
is traditionally considered to be the more active isoform in most PR sensitive tissues17,18
and differs from PR-A solely in the presence of an additional 164 amino acids at its N
terminal.19,20 The PRs are modular transcription factors containing two transcription
activation functions, AF-1 located in the N-terminal A/B domain, and AF-2 located
within the C-terminal ligand-binding domain.21 PR-B contains a third activation function,
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AF-3, in its unique N-terminal region.19 In addition to the direct actions of progesterone,
extracellular growth factors greatly influence PR signaling in the presence of
progestins.22,23 This pathway involves signaling from cell surface receptors and results in
phosphorylation of the progesterone receptor by mitogen activated kinases (MAPKs).24
Specifically, activation of PR by serum growth factors has been shown to involve
phosphorylation of serine 294 in the AF-1 region of PR through a Ras-Raf-MAPK
signaling pathway.25 Such MAPK-dependent phosphorylation is thought to augment
ligand-dependent transcriptional activation by PR, thereby enhancing the genomic effects
of PR. Of note, MAPK expression is elevated in many solid tumors26,27 and may play a
role in progesterone-mediated tumor growth.
In addition to soluble signaling by sex steroids, the importance of mechanical
signaling through extracellular matrix (ECM) – cell interactions has been increasingly
recognized as a major player in uterine physiology and pathophysiology. The
extracellular matrix is the main intermediary that conveys mechanical forces to the cell
membrane and from there to the intracellular space.28 In stiff tissues, which include many
tumors, exogenous forces (imposed by stiff matrices) and endogenous forces
(cytoskeletal tension) are functionally linked via Rho/ROCK/MAPK pathways.29
Specifically, matrix stiffness induces activation of membrane integrins,30 which in turn
activate RhoA. RhoA (often referred to simply as Rho) belongs to the Rho family of
small G-proteins. Small G-proteins are classified into five subgroups, the Ras, Ran, Rab,
Sar/Arf, and Rho families.30 The Rho family proteins, which include RhoA, Cdc42, and
Rac1, play an important role in cell morphology, adhesion, motility and growth after their
activation by numerous extracellular stimuli.30-32 When RhoA is activated by integrins, it
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propagates a signaling cascade that involves the activation of Rho-associated protein
kinase (ROCK) and subsequently myosin light chain (MLC), leading to the formation of
actin-myosin stress fibers and enhanced cell contractility.31,32 The resultant cytoskeletal
tension feeds back to the cell membrane to promote assembly of focal adhesion (FA)
complexes which help anchor the cell to the ECM.33 Cytoskeletal tension also drives
focal adhesion proteins to modify growth factor signaling through the mitogen-activated
kinase ERK 1/2—a modulator of cell growth.34,35 Thus, Rho indirectly drives ERK
dependent growth.29 Reciprocally, ERK can also induce ROCK and myosin light chain
activity.36,37 Finally, not only do cells respond to mechanical cues from the ECM, they
also help maintain and remodel the ECM through secretion of the various ECM
components and the molecules that degrade them, setting up a feedback loop of
reciprocal ECM-cellular interactions.
In fibroids, the ECM is excessive in amount and abnormal in content and
organization, leading to increased stiffness.38 Additionally, our group has recently found
that cells within a leiomyoma have an altered mechanical response to applied stress:
when normal myometrial cells are stressed, the cells orient perpendicular to the axis of
stress.39 Fibroid cells, on the other hand, fail to reorient their actin cytoskeleton in
response to applied stress. This implies that fibroid cells do not adequately perceive or
respond to mechanical queues, suggesting impairment in mechanical sensing. Thus,
fibroids have an abundant, abnormal and stiff ECM, but, paradoxically, the cells within
fibroids do not perceive that mechanical stiffness. These observations have led us to
postulate that attenuated mechanical sensing may contribute to fibroid pathogenesis by
creating a feed-forward cycle of excessive ECM deposition and growth.
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At the molecular level, the altered response to stress apparent in fibroids is
characterized by altered signaling of RhoA and over-expression of the Rho-GEF protein
Brx.38,39 Rho proteins, like other small G-proteins, exist in active GTP-bound and
inactive GDP bound forms,40,41 turning on and off the activity of their target molecules
via physical interactions.40 Guanine nucleotide exchange factors (GEFs), which contain
specific protein motifs characterized by the Dbl homology (DH) domain followed by the
pleckstrin homology domain, catalyze the conversion of the GDP-bound to the GTPbound form, indicating that this class of proteins plays an essential role in the activation
of small G-proteins.42,43 After regulating the activity of their target molecules, GTPbound small G-proteins are immediately returned to the GDP-associated form via their
intrinsic GTPase activity.40 Brx (Breast Cancer Auxiliary Factor) belongs to the Dbl
family of proto-oncogenes (reviewed in 44) that function as guanine nucleotide exchange
factors (GEFs) for Rho-GTPases. Its over-expression in fibroids shifts the balance of
Rho-GDP/Rho-GTP to the active, GTP bound states and thus promotes RhoA-mediated
fibroid growth.
Interestingly, Brx not only acts as a Rho family GEF but also binds to nuclear
hormone receptors via its C-terminal portion (nuclear receptor-interacting domain
(NRID)), which contains an leucine-rich LXXLL motif, and enhances transcriptional
activity of the estrogen receptors alpha45 and beta46 as well as the glucocorticoid
receptor.47 AKAP-Brx (also known as AKAP13) is a larger splicing variant of Brx
containing an additional 1389 amino-acid residues.48 This transcript possesses a protein
kinase A docking domain in its N-terminal portion and a full Brx sequence-containing
GEF domain and NRID at its C-terminal half.48
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In sum, both soluble signals, notably via the proliferative effects of estrogen and
progesterone, and mechanical signals, transduced from the extracellular matrix through
Rho-mediated pathways, are important for fibroid growth. AKAP-Brx, which is overexpressed in fibroids, is a unique protein in that it participates in both soluble and
mechanical signaling pathways. Collectively, these observations suggest that AKAP-Brx
could serve to integrate nuclear hormone receptor signaling with Rho-mediated
mechanical signaling in the uterus, and that dysregulated expression of the protein could
play a role in fibroid growth. However, despite what is already known about the
interaction of AKAP-Brx with the estrogen receptors, it is not known whether AKAP-Brx
also binds to progesterone receptor or augments progesterone action.
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Purpose and Specific Aims

As it is not known whether AKAP-Brx binds to progesterone receptor or
augments progesterone action, the present study was performed to investigate the effect
of AKAP-Brx on PR-B. Three specific aims were proposed:
-

Specific Aim 1: To test whether AKAP-Brx affects progesterone-dependent
gene regulation in leiomyoma cells.

-

Specific Aim 2: To test whether AKAP-Brx interacts with progesterone
receptor directly.

-

Specific Aim 3: To investigate putative mechanisms through which AKAPBrx would enhance PR-B activity, specifically via MAPK phosphorylation
pathways.

.
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Methods

All experiments were conducted by the author unless otherwise noted.
Plasmids— Progesterone-Response-Element luciferase (PRE-luciferase) and the
basal promoter TA-luciferase were purchased from Signosis. MMTV-luciferase, in which
the luciferase gene is under the control of a progesterone-responsive murine mammary
tumor virus (MMTV) promoter,49,50 and its associated basal promoter control (TKluciferase), were provided by Dr. Tomoshige Kino (NICHD, NIH, Bethesda, MD).
Expression plasmids for full-length AKAP-Brx were previously described.46 Human
progesterone receptor B (hPR-B) expressing plasmid was a generous gift of Dr. Stoney
Simons (NIDDK, NIH, Bethesda, MD). The empty bacterial expression vectors
pcDNA4-HisMax and pSG5 used as negative controls (for AKAP-Brx and PR-B,
respectively) are commercially available through Invitrogen and Agilent Technologies.
Expression of transfected proteins was confirmed via Western blot of transfected cell
lysates (data not shown).
Cell culture—African green monkey kidney COS7 cells were obtained from
American Type Culture Collection (ATCC) (Manassas, VA) and grown in Dulbecco’s
Modified Eagle Medium (DMEM) (GIBCO - Invitrogen) supplemented with 10% fetal
bovine serum (Fischer - Thermo Scientific), 100 units of penicillin, 1 ᶙg/ml of
streptomycin sulfate, and 2 mM L-glutamine (Invitrogen). Human breast carcinoma
T47D cells were also obtained from ATCC and grown in RPMI1640 (GIBCO –
Invitrogen) with the same supplements. Immortalized fibroid cell line was generated as
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described previously51 and grown in DMEM/F12 (GIBCO – Invitrogen) with the same
supplements.
Transient Transfection— Twenty-four hours before transfection, cells were
seeded in 24-well plates and grown to ~50% confluence in phenol-red free, 10%
charcoal-stripped fetal bovine serum preparations of the appropriate growth medium for
each cell type. Transfection was performed with FuGENE 6 (Roche Applied Science) or
HilyMax5 (Dojindo) per the manufacturer’s directions. The cells were co-transfected
with 0.3-0.5 ug/well of reporter plasmid, 0.3-0.5 ug/well of AKAP-Brx and 25 ng/well of
hPR-B expression plasmids. Total DNA was kept constant by addition of empty vector.
Twenty-four hours after transfection, 40 nM progesterone or EtOH vehicle dissolved in
medium was added to the cells. After an additional 24 h the cells were lysed with a
reporter lysis buffer (Promega), and the luciferase activities were determined using a
GloMax 96 Microplate Luminometer (Promega). Luciferase activities were normalized
by protein assay (Bradford, BioRad). The author acknowledges Tiffany Chu for her help
performing protein assays.
MAPK Inhibition Studies—Cells were seeded in 24-well plates and transfected as
described above. After transfection but prior to addition of hormone, cells were pretreated with the appropriate inhibitor: p38 MAPK inhibitors (2 uM SB202190 or 10 uM
SB203580 dissolved in DMSO) or a MEK 1/2 inhibitor (0.1, 1 or 10 uM UO126
dissolved in DMSO) for 1 hour. All inhibitors were purchased from Calbiochem. A
control group was treated with equivalent amounts of DMSO. After 1 hour of pretreatment, progesterone was added to each well to a final concentration of 40 nM without
changing the medium. After an additional 24 hours of progesterone treatment, cells were
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lysed and assayed as described above. The following experiments were conducted to
validate the activity of each inhibitor:
p38 MAPK inhibitors: Cos7 cells were seeded in 6-well plates and grown to 50%
confluence. Cells were then treated for an hour with the appropriate inhibitor or DMSO,
after which they were shocked with 50% sorbitol for 30 minutes, which is known to
induce phosphorylation of p38 MAPK.52 Cells were extracted and lysates resolved via
SDS-PAGE. Gels were blotted onto PVDF membranes and probed with anti- p38 MAPK
antibodies (phosphorylated and pan). Immune complexes were detected using enhanced
chemiluminescence (Pierce) as per manufacturer's directions. Relative protein
concentrations in the presence and absence of inhibitor were analyzed via densitometry.
MEK 1/2 inhibitors: Cos 7 cells were seeded in 6-well plates and grown to 50%
confluence in serum-free media. Cells were then treated with 1 uM UO126 or DMSO for
one hour. Serum was subsequently reintroduced to the medium to induce p42/44 MAPK
(ERK 1/2) activation. Cells lysates were resolved in SDS ± PAGE, blotted to PVDF and
probed with anti-phosphorylated p42/44 MAPK (ERK1/2) antiserum. Protein
concentrations in the presence and absence of inhibitor were analyzed via densitometry.
siRNA Interference—These experiments were conducted by Dr. Paul H. Driggers.
T47D human breast-cancer cells were employed for these experiments as they retain
endogenous PR-B expression after immortalization. T47D cells were seeded in 24-well
plates and grown to 30-50% confluence in phenol-red-free media supplemented with
charcoal stripped serum (without antimicrobials). Cells were transfected with 20 pmol
AKAP-Brx siRNA per well or equal amounts of scrambled siRNA. Transfection was
performed with Lipofectamine (Invitrogen). After 24 hours, increasing amounts of
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progesterone (0, 0.5, 1.0, 5.0, 10, 20 or 40 nM) were added to respective wells. Cells
were lysed and assayed for activity of the PR-controlled gene alkaline phosphatase after
24 hours.
GST-binding studies—Full transcript AKAP-Brx (termed FT) or a 1.8 kb
fragment corresponding to region 5 (near the C terminal) of AKAP-Brx (termed R5) were
sub-cloned in-frame into the bacterial expression plasmid pGEX2TKB. Recombinant
GST-FT, GST-N5 and GST-0 control proteins were induced and purified as per
manufacturer's instructions (Pharmacia). PR constructs were generated by PCR
amplification from the pSG5-hPR-B plasmid using the following oligonucleotides: (1): 5'
CGAAATTAATACGACTCACTATAGGGAGACCCACCATGGTGCTGATCAACCT
GTTAATGAGC 3', and (2) 5' TCACATCTTTTTATGAAAGAGAAGGGG 3'. The
forward primer contained a T7 sequence for recognition by rabbit reticulocyte RNA
polymerase. Fragments were then transcribed and translated in vitro (TNT, Promega).
100 000 c.p.m. of 35S-labeled PR protein constructs were incubated with GST-constructcoated beads for 1 h at 4°C in HBB (40mM HEPES, 75 mM KCl, 0.5 mM EDTA, 5 mM
MgCl2, 1 mM DTT, 1 mM AEBSF, bovine serum albumin 0.5 mg/ml, and 0.05% nonidet
P40). After five wash steps in HBB, bound proteins were eluted in sample buffer and
analysed by SDS ±PAGE and auto-radiography. 10 000 c.p.m. were loaded for each input
lane. The luciferase protein, which does not bind to AKAP-Brx, was in vitro transcribedtranslated using a template provided by the manufacturer (TNT, Promega) and served as
a negative control. In vitro transcribed-translated estrogen receptor (ER) was used as a
positive control, as it has been shown to bind AKAP-Brx in past experiments.45
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Mammalian Two Hybrid Plasmids—The GAL4-luciferase reporter was
constructed by amplification of GAL45E1b promoter sequences from pGAL45E1bCAT
and subcloned into pGL2-Basic (Promega) as previously described.45 DBD (pM) empty
vector and AD (VP16) empty vector were obtained commercially (Matchmaker
Mammalian Assay Kit, Clontech). A 738 base pair fragment of PR corresponding to
amino acids 687 through 933 of the C terminal of PR (termed PR687C) was created by
PCR amplification from the full length hPR-B plasmid using the following primers: (1)
5’

AGCGGCGAATTCCTGATCAACCTGTTAATGAGC

3’

and

(2)

5’

CCCCGGGAATTCTCACTTTTTATGAAAGAGAAG 3’. The forward primer contains
an XbaI recognition sequence followed by a Kozak sequence and the appropriate base
pairs of hPR-B cDNA. The reverse primer contains the EcoRI recognition sequence,
Kozak sequence and the appropriate base pairs of hPR-B cDNA. The PCR amplification
product was subcloned into the commercial DBD empty vector via XbaI / EcoRI sites
and the resultant vector transformed into competent cells. Recombinants were isolated via
analytic gel electrophoresis and these were further digested to confirm correct
directionality.
A 2.1 kb PR fragment corresponding to amino acids 1 through 687 and termed
PR687N was amplified from the same hPR-B template using the following primers: (1)
5’ ACTGTATCGCCGGAATTCATGACTGAGCTGAAGGCAAAG 3’ (containing the
EcoRI recognition sequence, Kozak sequence, and appropriate base pairs of hPR-B
cDNA) and (2) 5’ ACGGATCCCCGGGAATTCTGGTGGAATCAACTGTATGTC 3’
(containing the EcoRI recognition sequence, Kozak sequence, and appropriate base pairs
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of hPR-B cDNA). The resulting PCR product was cloned into the DBD empty vector
between the EcoRI site and processed in a similar manner as above.
AD-AKAP-Brx was constructed by amplification of the nuclear localization
sequence and VP16 activation domain from pNLVP16. The resulting fragment was fused
to the open reading frame of the 1.8 kb AKAP-Brx cDNA by overlap amplification and
subcloned into the mammalian expression vector pBK-RSV as described previously.45
Constructs were tested for expression of full-length proteins by Western Blot
analysis of extracts of transfected cells, using anti-GAL4 DNA binding domain and antiVP16 antibodies (Santa Cruz). Constructs were also partially sequenced for confirmation.
The author is grateful to Alexandra Poch for her help in generating these plasmids.
Ex vivo binding studies (Mammalian-2-Hybrid System)—Cells were grown in 24well plates to 50% confluence prior to HilyMax (Dojindo) transfection with 500 ng ADAKAP-Brx, 100 ng DBD-PR(687C) or DBD-PR(687N), and 100 ng GAL4-luciferase
reporter. Six hours after transfection cells were treated with 1 uM progesterone and were
harvested 24 h thereafter.
Statistical Analysis—Statistical analysis was carried out by Student’s t test for
unpaired samples with the two-tailed p value. All experiments were repeated at least
twice, and representative results are shown in the figures.
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Results

AKAP-Brx Enhances Ligand-dependent Transcriptional Activation by PR-B—
Given

our

previous

observations

that

AKAP-Brx

enhances

ligand-dependent

transcriptional activation by several nuclear hormone receptors, including ER-α45, ER-β46
and GR47, we wanted to test whether AKAP-Brx expression could also affect the ability
of PR-B to activate a reporter. We first tested Cos7 cells, which are devoid of both
endogenous AKAP-Brx as well as nuclear progesterone receptors, as they constituted a
“clean” system in which to isolate the functions of our proteins of interest. Two different
hormone-responsive promoters were utilized—one specific to progesterone (PREluciferase) and one highly sensitive to steroid hormones (MMTV-luciferase)49,50—to test
the robustness of the system. As expected, transfection of PR-B alone into Cos7 cells
resulted in several fold ligand-dependent activation of the PRE-luciferase reporter (Fig.
1A, solid black bar) and of the MMTV-luciferase reporter (Fig. 1B, solid black bar) in
Cos7 cells. Co-transfection of an expression vector for full-length AKAP-Brx enhanced
ligand-dependent transactivation by PR-B almost two-fold for PRE-luciferase (Fig. 1A,
hashed black bar, p< 0.01) and five-fold for MMTV-luciferase (Fig. 1B, hashed black
bar, p < 0.0001). In the absence of ligand, no induction of luciferase activity was
observed (Fig. 1A and 1B, hashed white bars). These results suggest that the full level of
activity of PR-B in the presence of AKAP-Brx was dependent on activation of the
receptor by ligand binding. We also tested the specificity of AKAP-Brx action by
assessing the ability of Brx to activate the basal promoters TA-luciferase and TKluciferase. AKAP-Brx failed to activate these basal promoters (Fig. 1A and 1B, four
right-most bars). Finally, we tested this paradigm in a line of immortalized uterine
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leiomyoma cells, which were derived from human fibroid tissue from surgical specimens.
Previous research indicates that gene expression profiles of these cells closely resemble
the parent cells.51 Once again, we confirmed that co-transfection of AKAP-Brx enhanced
ligand-dependent gene activation by PR-B by four-fold for the PRE-luciferase reporter
(the weaker and more specific of the two hormone responsive luciferase promoters based
on the Cos7 experiments) (p < 0.01) (Fig. 1C).
Silencing of AKAP-Brx expression via RNA-interference decreases the activation
of an endogenous progesterone responsive gene by progesterone in a dose-dependent
manner—The activity of alkaline phosphatase, a gene known to be progesterone
responsive, in PR+ T47D breast cancer cells was reduced by 50% in the presence of
AKAP-Brx interference RNA, when these cells were treated with varying amounts of
progesterone. The effect was most pronounced with increasing amounts of the hormone,
from 1 to 40 nM. These results suggest that expression of AKAP-Brx is necessary for the
full activation of this progesterone-responsive gene in the presence of a wide range of
progesterone concentrations (Fig. 2).
The C-terminal of PR binds to AKAP-Brx in-vitro. To test whether PR could bind
directly to AKAP-Brx, a fragment of PR corresponding to amino acids 687 through the C
terminal (amino acid 933) was created via PCR amplification of the full length hPR-B
bacterial plasmid and in vitro transcribed-translated in the presence of S-35 labeled
methionine. This fragment, designated PR687C, is common to both PR-A and PR-B and
contains the AF-2 activation function of the protein as well as the hormone binding
domain, as illustrated in Figure 3A. In parallel, GST-AKAP-Brx fusion chimeras were
generated from bacterial plasmids and immobilized on sepharose beads. Two chimeras
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were proposed: a full length AKAP-Brx construct (designated “FT’) and a fragment
corresponding to region 5 of the protein (designated “R5”). R5 contains the leucine-rich
motif (LXXLL) of AKAP-Brx, which has been previously shown to bind the nuclear
hormone receptors ER-α, ER-β, and GR. This domain has been therefore designated a
nuclear-receptor-interacting domain (NRID). The construction of AKAP-Brx chimeras is
illustrated in Figure 3A. Results of the pull down assay demonstrate that PR687C bound
to both full-transcript AKAP-Brx as well as the smaller, NRID containing, fragment.
PR687C did not bind to empty non-chimeric glutathione transferase (GST-O)
immobilized on sepharose beads (Fig. 3A). As a negative control, radiolabeled luciferase
failed to bind to either full-length or truncated AKAP-Brx (Fig. 3B). As previously
reported, radiolabeled estrogen receptor did bind to both AKAP-Brx chimeras (Fib. 3C).
AKAP-Brx and the C-terminal of PR interact in mammalian cells. Next, we tested
whether AKAP-Brx and PR687C could interact ex-vivo in mammalian cells. To this end,
the PR687C fragment was fused to a GAL4 DNA binding domain (DBD-PR687C) and
transfected into Cos7 cells. In a similar fashion, AKAP-Brx was fused with the VP16
activation domain (AD-AKAP-Brx) and co-transfected into the cells. Results demonstrate
that DBD-PR687C by itself can activate a GAL4 luciferase several fold in the presence of
progesterone ligand. This is not surprising as PR687C contains a hormone-bindingdomain as well as an intrinsic activation domain (AF-2), which, when coupled to the
GAL4 DBD, are sufficient to induce GAL4-luciferase activity. Co-transfection of ADAKAP-Brx doubled this activation profile (p < 0.05), suggesting that the two proteins
interact directly within live cells. Interestingly, this effect was only seen in the presence
of progesterone, suggesting that AKAP-Brx and PR interaction is dependent upon
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hormone binding (Fig. 4A). On the contrary, when a PR687N construct (expressing
amino acids 1-687 from the N terminal of PR-B) fused to the GAL4-DBD was tested in
the same manner, it failed to induce ligand-dependent receptor activity and was not
influenced by co-transfection of AD-AKAP-Brx (Fig. 4B). This implies that the
hormone-binding-domain-containing, C terminal region of PR is necessary for interaction
with AKAP-Brx. It should be noted that activation of luciferase in the presence of DBDPR687N is higher than the baseline activation profile of the unfused GAL-DBD control.
This could be due to the actions of AF-1 and/or AF-3 contained in PR687N; however,
this activation profile is unaffected by either progesterone ligand or by co-expression of
AKAP-Brx. Expression of the transfected fusion proteins (AD-AKAP-Brx, DBDPR687C and DBD-PR687N) in Cos7 cells was confirmed by immunohistochemical
detection using antibodies directed against VP16 or GAL4 (data not shown).
AKAP-Brx Signaling to PR-B Does Not Involve p38 MAPK—Analogous to other
members of the steroid receptor superfamily, progesterone receptors are highly
phosphorylated and therefore sensitive to growth factor-initiated signaling pathways. We
previously reported that AKAP-Brx augments ligand-dependent activity of ER-β via a
p38 MAPK dependent pathway.46 We thus asked whether AKAP-Brx may signal to PRB through this pathway as well. The pyridinyl imidazole compounds SB202190 and
SB203580 inhibit the α and β isoforms of p38 MAPKs by a mechanism involving direct
binding to the kinases.53 In our transient transfection system using PR-B and the MMTVluciferase reporter, co-transfection of AKAP-Brx enhanced ligand-dependent activity of
PR-B to levels 15-fold that of baseline activation (Fig. 5A, left-most dark bar), consistent
with the activation profile seen in Fig 1B. Addition of either 2 uM SB202190 or 10 uM
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SB203580 did not affect the enhancement of ligand-dependent activity of PR-B by Brx
(Fig. 5A, center and right-most dark bars), suggesting that p38 MAPK activity is not
required for enhancement of ligand-dependent activity of PR-B. In control experiments,
the same concentration of inhibitors effectively inhibited p38 MAPK phosphorylation in
sorbitol-shocked cells (Fig. 5B).
AKAP-Brx Activates PR-B by a p42/44 MAPK (ERK1/2) Dependent Pathway—
because activation of PR-B by Brx did not appear to involve p38 MAPK pathways, we
tested whether the enhancement of PR-B activity by Brx could involve an alternative
phosphorylation pathway. PR-B has been shown to be activated in a ligand-dependent
manner by a mechanism involving phosphorylation of Ser 294 residue through the RasRaf-p44/42 MAPK (ERK1/ERK2) signaling pathway.25 It has also been shown that the
Rho protein Cdc42 can activate ERK2 in cooperation with Raf.54 We therefore tested
whether activation of PR-B by Brx involves ERK1/2. Dual specificity mitogen-activated
protein kinase kinases (MEK) activate ERK by phosphorylating specific Thr and Tyr
residues. The inhibitor UO126 is thought to block activation of ERK55 by binding to
inactive MEK1 and blocking activation by upstream kinases.16 In our transient
transfection system using PR-B expressed as a bacterial plasmid and the MMTVluciferase reporter, transfection of PR-B activated luciferase expression several fold in
the presence of ligand compared with control transfections lacking ligand. Cotransfection of AKAP-Brx enhanced ligand-dependent activity of PR-B over 2-fold (Fig.
6A). Addition of 1 uM UO126 inhibited activation of PR-B by AKAP-Brx by 40% (p <
0.0001), suggesting that ERK1/2 activity is required for enhancement of liganddependent activity of PR-B by AKAP-Brx. In control experiments, 1 uM UO126
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effectively inhibited ERK1/2 phosphorylation induced by serum growth factors (data not
shown).
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Discussion

Previously, AKAP-Brx has been reported to activate several nuclear hormone
receptors including estrogen receptors alpha45 and beta46 and glucocorticoid receptor47.
Here we show for first time that AKAP-Brx also increases ligand-dependent gene
activation by PR-B. Our results are reproducible in different cell types (Cos7, fibroids)
and with different progesterone-responsive reporter genes. Conversely, silencing of
AKAP-Brx via RNA interference decreases expression of progesterone-dependent genes
in PR+ cells. While we don’t know the exact mechanism through which AKAP augments
PR-B action, it appears to require p42-44 MAPK (ERK1/2). This is in contrast to AKAPBrx- mediated activation of ER, which required p38 MAPK signaling, but not ERK1/2.46
In-vitro and ex-vivo studies suggest that there is direct interaction between AKAP-Brx
and PR-B, as is evident for the estrogen receptors45,46 as well as the glucocorticoid
receptor.47 Furthermore, direct binding occurs via a LXXLL-containing nuclear receptor
interaction domain (NRID) on AKAP-Brx and through PR’s conserved ligand binding C
terminus.
A working model integrating the multiple known functions of AKAP-Brx with
the newfound data of its interaction with PR-B is proposed in Figure 7. In this model,
AKAP-Brx is conceptualized as a scaffold protein, capable of bringing in close
proximity, at the sub-cellular level, the different players involved in extracellular signal
transduction—which includes both mechanical signals (notably matrix stiffness) and
extracellular growth factors—with steroid hormone signaling. On the one hand, matrix
stiffness activates Rho/ROCK and ERK pathways, ultimately leading to cytoskeletal
tension, focal adhesion complex formation, and growth. At the same time, AKAP-Brx
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binds PR via its LXXLL containing nuclear receptor interaction domain (NRID) when
the receptor is bound to progesterone. It subsequently augments PR-B transcriptional
activity through ERK1/2 phosphorylation. While we do not know the exact mechanism
underlying the enhancement of PR-B activity by ERK1/2, we hypothesize that it may
involve signaling via Rho. If this is the case, it is possible that, in fibroids, activation of
Rho—by increased matrix stiffness and/or AKAP-Brx over-expression—enhances ERK
activity, leading to PR phosphorylation and increased transcription of genes involved in
cellular proliferation. AKAP-Brx therefore provides a possible point of convergence
between Rho-mediated (mechanical) signaling and progesterone-mediated (soluble)
signaling in fibroids. In this paradigm, the effects of even low-to-normal levels of
circulating progesterone would become amplified through Rho-ERK-PR transduction
pathways, raising the interesting possibility that fibroid cells might be relatively
insensitive to reductions in circulating progesterone, a condition that could contribute to
fibroid pathogenesis and survival. This would explain why fibroid development, though
favored by high-progesterone states, is not restricted to such periods and why some
women do not respond to treatment with SPRMs.
This study has several limitations. First, all experiments were conducted in cell
culture. Ideally, our findings should be extended to in-vivo mouse models. Second,
immortalized fibroid cells lose their endogenous progesterone receptor activity and we
thus had to transfect exogenous human PR-B in order to demonstrate our findings.
Working with primary cell cultures may bypass this problem in the future. However, the
lack of endogenous PR in fibroid cells did allow us to isolate our findings to the PR-B
isoform, which would otherwise have been difficult. Third, while we were able to isolate
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the AKAP-Brx binding sites of PR-B to amino acids 687 through 933, we were not able
to produce full-length progesterone receptor B for the purpose of our GST-pull-down
binding studies. Reversing the direction of the constructs (GST-PR and S35-labeled
AKAP-Brx) may be an alternative approach. Finally, the role of AKAP-Brx’s PKAbinding and Rho-GEF domains need to be examined more directly in relation to MAPK
and PR signaling.
Certainly, further studies are needed to continue to elucidate the relationship
between progesterone, AKAP-Brx and MAPK, and how their signaling interactions
culminate in increased leiomyoma growth. We hope that, in time, the augmenting
understanding of this important topic may lead to new treatments for fibroids and
potentially other highly prevalent uterine conditions such as pre-term birth, which affect
millions world-wide.
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Figure 1
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Figure 1. AKAP-Brx augmented ligand-dependent gene-activation by progesterone
receptor B. (a) Cos7 cells plated in 24-well plates were transiently transfected with
expression vectors for AKAP-Brx (0.3-0.5 ug), PR-B (25 ng) and a luciferase reporter
containing a progesterone-response-element (PRE) promoter (0.3-0.5 ug). A luciferase
reporter containing the basal TA promoter was used as a control. Amount of transfected
DNA was kept constant by the addition of empty vector. After 24 hours, cells were
treated with 40 nM progesterone and assayed for luciferase activity 24 hours later.
Expression of AKAP-Brx resulted in a 1.7 fold increase in PRE-luciferase activity in the
presence of progesterone (**p < 0.01), while no effect was seen in the absence of
progesterone or with the TA-Luc basal promoter. (b) Cos7 cells were transfected with a
luciferase reporter plasmid containing the hormone responsive mouse mammary tumor
virus (MMTV) promoter (0.3 to 0.5 ug) and otherwise handled as above. A luciferase
reporter containing the basal tirosine-kinase (TK) promoter was used as a control.
Expression of AKAP-Brx resulted in a 5 fold increase in MMTV-luciferase activity in the
presence of progesterone (***p < 0.0001), while no effect was seen in the absence of
progesterone or with the TK-luciferase basal promoter. (c) Fibroid cells were transfected
with PRE-luciferase and handled as above. Expression of AKAP-Brx resulted in a 4 fold
increase in PRE-luciferase activity in the presence of progesterone (**p < 0.01), while no
effect was seen in the absence of progesterone or with the TA-Luc basal promoter.
Luciferase values represent fold-activation (mean) over control (the respective luciferase
reporter in the absence of ligand and AKAP-Brx). Each graph represents data from four
experiments conducted in triplicate, n = 12 per bar. Error bars represent standard error of
the mean (SEM).
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Figure 2
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Figure 2. Silencing expression of AKAP-Brx via RNA interference reduced
activation of an endogenous progesterone-responsive gene in the presence of
progesterone hormone, in a dose-dependent manner. T47D cells were seeded in 24well plates and grown to 30-50% confluence in phenol-red-free media supplemented with
charcoal-stripped-serum. Cells were transfected with 20 pmol AKAP-Brx siRNA or
equal amounts of scrambled negative control siRNA (ASN) per well. After 24 hours,
increasing amounts of progesterone (0, 0.5, 1.0, 5.0, 10, 20 or 40 nM) were added as
indicated. Cells were lysed and assayed for activity of the PR-controlled gene alkaline
phosphatase after an additional 24 hours.
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Figure 3
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Figure 3. Interaction between AKAP-Brx and PR in vitro.

(a) GST-AKAP-Brx

chimeric fusion proteins were created by subcloning AKAP-Brx (full length (FT) and
region 5 fragment (R5)) into the bacterial expression plasmid pGEX2TKB. Fragments of
PR from amino acid 687 to the C terminus were in vitro transcribed-translated in the
presence of S-35 labeled methionine. 35S-methionine labeled PR was incubated with
bacterially expressed GST-AKAP-Brx transcripts (FT or R5), or GST alone (GST-0),
coupled to glutathione-Sepharose beads. Bound proteins were resolved using SDS±
PAGE and visualized by autoradiography. Results show the PR687C bound to both full
transcript AKAP-Brx and R5 AKAP-Brx, but not to the negative control GST-O. (b)
Negative control: Luciferase did not bind to AKAP-Brx. (c) Positive control: As
previously reported, ER bound to AKAP-Brx.45 Representative results of 6 experiments
are shown.
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Figure 4
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Figure 4. Interaction between AKAP-Brx and PR in mammalian cell culture.
Expression plasmids encoding the LXXLL-motif-containing Region 5 of AKAP-Brx
fused to the VP16 transcription activation domain (AD) and/or PR constructs fused to the
GAL4 DNA binding domain (DBD) were transfected as indicated into Cos7 cells
together with a GAL4-luciferase reporter (present in all lanes). (a) The ligand-binding
region of PR (from amino acid 687 to the C terminus) was tested against AKAP-Brx.
Transfection of DBD-PR(687C) alone resulted in hormone-dependent activation of the
luciferase reporter, which was an expected finding given the intrinsic activation domain
contained by this region of PR (AF-2). Co-transfection of AKAP-Brx doubled this
activation (*p < 0.05), suggesting that the two proteins can interact directly in cells. (b)
The N terminal region of PR (from amino acid 1 to amino acid 687) was tested against
AKAP-Brx. As expected, there was no hormone-dependent activation of luciferase, as the
N-terminal region of PR does not contain a hormone-binding-domain. While the basal
luciferase expression was higher when DBD-PR(687N) was transfected (over the empty
DBD and AD vectors) this increase was non-specific and was not enhanced by cotransfection of AD-AKAP-Brx, suggesting that AKAP-Brx requires the C terminal of PR
to bind the protein. For both graphs, luciferase activity is depicted as fold induction
(mean) over control (reporter and empty vectors). Three experiments were performed in
triplicate, n=9 per bar. Errors bars represent SEM. Expression of transiently transfected
fusion proteins (AD-AKAP-Brx, DBD-PR687C and DBD-PR687N) in Cos7 cells was
confirmed by immunohistochemical detection using antibodies directed against VP16 or
GAL4 (data not shown).
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Figure 5. Augmentation of PR-B activity by AKAP-Brx was not affected by the
inhibition of p38 MAPK activity (a) the p38 MAPK inhibitors SB202190 and
SB203580 did not inhibit the activity of AKAP-Brx. Cos7 cells were transfected with 0.5
ug of a MMTV-luciferase reporter plasmid and 0.5 ug of an expression vector for AKAPBrx, along with 25 ng of hPR-B. SB202190 (2 uM), SB204580 (10 uM) or DMSO
vehicle were added as indicated. Cells were treated with 40 nM progesterone versus
EtOH vehicle as shown. Luciferase values represent -fold activation (with activation
given by MMTV-luciferase in the absence of ligand arbitrarily assigned a value of 1.0)
from three experiments performed in triplicate or quadruplicate, n=10 per bar. Error bars
represent SEM. (b) Inhibitor efficacy was tested by sorbitol shocking cells in the
presence or absence of the respective inhibitor. Cell lysates were resolved by SDSPAGE, blotted in PVDF and probed for p38 MAPK (phospho-specific and pan). Relative
protein concentrations were analyzed by densitometry as shown at right. Results
demonstrate that both inhibitors decreased phosphorylated p38 MAPK by 70% compared
to the no-inhibitor + sorbitol condition. Representative results of three experiments are
shown.
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Figure 6
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Figure 6. Activation of PR-B by AKAP-Brx was dependent on p42/44 (ERK1/2)
activity. (a) Activation of PR-B by AKAP-Brx was inhibited by the MEK inhibitor
UO126 at 1 uM and 10 uM doses. Cos7 cells were transfected with 0.5 ug of a MMTVluciferase reporter plasmid and expression vectors for hPR-B (25 ng) and AKAP-Brx (0.5
ug) or the same amounts of empty expression vectors. Progesterone (40 nM, dark bars) or
vehicle control (EtOH, light bars) and increasing doses of UO126 or control (DMSO)
were added as indicated. Cells were harvested after 24 h. Luciferase values represent
fold-activation (mean) over control (MMTV-luciferase in the absence of ligand, inhibitor,
and AKAP-Brx plasmid) compiled from two experiments conducted in duplicate for the
0.1 uM UO126 and 10 UO126 conditions (n=4 per bar) and five experiments conducted
in triplicate for the DMSO and 1 uM UO126 conditions (n=15 per bar). Error bars
represent SEM. (b) As a control, the same paradigm as in (a) was tested using the basal
tk-luciferase, which yielded no luciferase activity for any condition, as expected.
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Figure 7. Working model of the relationship between AKAP-Brx, Progesterone
Receptor, and ERK signaling pathways. AKAP-Brx is a scaffold protein which
localizes at the subcellular level the different players involved in extracellular signal
transduction (both mechanical signals and growth factor signals) and steroid hormone
signaling. AKAP-Brx binds PR via its LXXLL containing nuclear receptor interaction
domain (NRID) when the receptor is bound to progesterone. It subsequently augments
PR-B transcriptional activity through a pathway involving ERK1/2. While the
mechanism underlying the enhancement of PR-B activity by ERK1/2 remains unknown,
it may involve signaling via Rho (hashed arrow). Abbreviations: cAMP = cyclic
adenosine monophosphate. PKA = protein kinase A. CI and CII = catalytic domains 1
and 2. RI and RII = regulatory domains 1 and 2. Ht31 = PKA binding domain. GEF =
guanine-exchange factor domain. NRID = nuclear receptor interaction domain. PR =
progesterone receptor. PRE = progesterone response element.

